Usefulness of Once-Weekly GLP-1 Receptor Agonist Semaglutide on Glycemic Control in Subjects with Type 2 Diabetes Mellitus: Switching from the Same Class Dulaglutide in a Retrospective Observation Study

Table 2

Dose of dulaglutide and semaglutide at baseline and 3 months and 6 months after switching. (a) Study 1. (b) Study 2.

(a)

Dose	At baseline, (%)	After 3 months, (%)	After 6 months, (%)
0.25 mg	16 (84%)	3 (16%)	0 (0%)
0.5 mg	3 (16%)	14 (74%)	10 (53%)
1.0 mg	0 (0%)	2 (11%)	9 (47%)
Average dose

(b)

Dose		At baseline, (%)	After 3 months, (%)	After 6 months, (%)
Dula	0.75 mg	13 (100%)	13 (100%)	13 (100%)
	0.25 mg	11 (85%)	3 (23%)	0 (0%)
Sema	0.5 mg	2 (15%)	8 (62%)	7 (54%)
	1.0 mg	0 (0%)	2 (15%)	6 (46%)
Average dose